CLINICAL TRIALS PROFILE FOR ROBINUL FORTE

All Clinical Trials for Robinul Forte

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00579085 ↗	Double Blind Placebo Controlled Study of Outpatient Intravenous Ketamine for the Treatment of CRPS	Completed	Drexel University College of Medicine	Phase 2	2006-09-01	Complex Regional Pain Syndrome is a debilitating and extremely difficult to treat condition. There is a large body of evidence demonstrating the therapeutic value of N-methyl-D-aspartate (NMDA)-receptor antagonists in CRPS. The NMDA antagonist ketamine has been shown to be effective in the treatment of CRPS, resulting in complete remission of the disease in some patients. The purpose of this study is to evaluate intravenous outpatient infusion of sub-anesthetic doses of ketamine for the treatment of CRPS. A thorough evaluation of this procedure, providing information into the degree of relief and which of the constellation of RSD symptoms are best alleviated by this procedure would result in the optimization of this therapy for the treatment of CRPS.
NCT01191398 ↗	Effectiveness of Atropine and Glycopyrrolate to Reduce Hyper Salivation With Ketamine Sedation	Completed	Craig J. Huang	N/A	2010-06-01	The purpose of this study is to determine if the antisialagogues (anti-salivary agents), Atropine and Glycopyrrolate, are effective in reducing hypersalivation when sedating patients with Ketamine for procedural sedation in the emergency department or abscess clinic. The investigators will measure salivary flow rate by collecting oral secretions by oral suctioning over a 30 minute time period starting with the administration of Ketamine. The investigators hypothesize that patients who receive either atropine or glycopyrrolate will have fewer oral secretions than patients who receive placebo.
NCT02872935 ↗	Minimizing Nausea and Vomiting During Spinals for CS	Terminated	Kokila N Thenuwara	Phase 4	2015-05-15	In parturients undergoing Cesarean section under spinal anesthesia, co-loading of 1 liter of crystalloids, with placing the spinal, along with administering a phenylephrine infusion and glycopyrrolate, enables placing a spinal with minimal perioperative nausea and vomiting and good intra and post-operative pain relief.
NCT02872935 ↗	Minimizing Nausea and Vomiting During Spinals for CS	Terminated	University of Iowa	Phase 4	2015-05-15	In parturients undergoing Cesarean section under spinal anesthesia, co-loading of 1 liter of crystalloids, with placing the spinal, along with administering a phenylephrine infusion and glycopyrrolate, enables placing a spinal with minimal perioperative nausea and vomiting and good intra and post-operative pain relief.
NCT03513757 ↗	Dexmedetomidine and Propofol for Pediatric MRI Sedation	Completed	Medical College of Wisconsin	Phase 4	2018-03-04	The purpose of this study is to compare the results of combining two anesthetic medications (dexmedetomidine and propofol) in low doses with a standard dose of a single drug that is commonly used to provide sedation/anesthesia for MRI studies in young children (propofol). The drugs used for the MRI scan in this study will be chosen randomly. Half the patients will receive small doses of propofol and dexmedetomidine. The other half will receive propofol administered constantly throughout the scan. Other drugs that may be used include sevoflurane and nitrous oxide at the start of the sedation (for placing an intravenous), lidocaine (to reduce the pain of propofol injection) and glycopyrrolate (to prevent the heart rate from decreasing too low. The investigators will record 5 additional blood pressures and heart rates. If additional medications are required to complete the scan, the investigators will administer whatever is necessary. At the end of the study, the investigators will have an observer record the time it takes for participants to spontaneously open eyes , to be able to drink liquids and/or eat and to behave as before the study. Also, it is very important that the investigators find out from participants about changes in behavior, or if eating or sleeping habits were unusual following completion of the study. For that reason, the investigators will call participants in a day or so following the MRI scan. The investigators expect to recruit 40 children between the ages of 12 and 72 months for the study and hope to have the study completed in December 2018.

Clinical Trial Conditions for Robinul Forte

Condition Name

Condition Name for Robinul Forte
Intervention	Trials
Surfactant Deficiency Syndrome Neonatal	1
Abdominal Neoplasm	1
Tumor	1
Complex Regional Pain Syndrome	1

Condition MeSH

Condition MeSH for Robinul Forte
Intervention	Trials
Critical Illness	1
Sialorrhea	1
Hydrocephalus	1
Respiratory Distress Syndrome, Newborn	1

Clinical Trial Locations for Robinul Forte

Trials by Country

Trials by Country for Robinul Forte
Location	Trials
United States	4
Finland	1
Canada	1

Trials by US State

Trials by US State for Robinul Forte
Location	Trials
Wisconsin	1
Iowa	1
Texas	1
Pennsylvania	1

Clinical Trial Progress for Robinul Forte

Clinical Trial Phase

Clinical Trial Phase for Robinul Forte
Clinical Trial Phase	Trials
Phase 4	3
Phase 2	1
N/A	2

Clinical Trial Status

Clinical Trial Status for Robinul Forte
Clinical Trial Phase	Trials
Completed	3
Terminated	1
Unknown status	1

Clinical Trial Sponsors for Robinul Forte

Sponsor Name

Sponsor Name for Robinul Forte
Sponsor	Trials
McGill University Health Center	1
McGill University Health Centre/Research Institute of the McGill University Health Centre	1
Drexel University College of Medicine	1

Sponsor Type

Sponsor Type for Robinul Forte
Sponsor	Trials
Other	9